Company to Evaluate Dual Listing on HKEX

AI SummaryClose X

Allergy Therapeutics PLC announced on 6 November 2025 its exploration of a dual primary listing on the Main Board of The Stock Exchange of Hong Kong Limited (HKEX), alongside its existing London Stock Exchange AIM market listing. This strategic move aims to expand the company's presence in Asia, enhance trading liquidity, and broaden its investor base to include Hong Kong and mainland Chinese investors, aligning with its global leadership ambitions in allergy treatments. The company targets the HKEX listing to become effective during the first half of 2026, contingent on market conditions and regulatory approvals, which could positively impact future growth and share price by increasing market access and investor engagement.

Disclaimer*

UK 100

Latest directors dealings